PGEN

Precigen (PGEN)

Precigen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PGEN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/17	05 : 30	PR Newswire (US)	Precigen to Participate in the 2024 Cantor Global Healthcare Conference	NASDAQ:PGEN	Precigen Inc
2024/08/31	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PGEN	Precigen Inc
2024/08/15	05 : 25	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PGEN	Precigen Inc
2024/08/15	05 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PGEN	Precigen Inc
2024/08/15	05 : 05	PR Newswire (US)	Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates	NASDAQ:PGEN	Precigen Inc
2024/08/14	06 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/08/09	22 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PGEN	Precigen Inc
2024/08/09	21 : 00	PR Newswire (US)	Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th	NASDAQ:PGEN	Precigen Inc
2024/08/09	05 : 19	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PGEN	Precigen Inc
2024/08/08	10 : 30	PR Newswire (US)	Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock	NASDAQ:PGEN	Precigen Inc
2024/08/07	05 : 46	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PGEN	Precigen Inc
2024/08/07	05 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PGEN	Precigen Inc
2024/08/07	05 : 04	PR Newswire (US)	Precigen Announces Proposed $30 Million Public Offering of Common Stock	NASDAQ:PGEN	Precigen Inc
2024/08/07	05 : 01	PR Newswire (US)	Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch	NASDAQ:PGEN	Precigen Inc
2024/07/25	06 : 21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/07/25	06 : 20	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/07/23	21 : 01	PR Newswire (US)	Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch	NASDAQ:PGEN	Precigen Inc
2024/06/03	22 : 30	PR Newswire (US)	Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response	NASDAQ:PGEN	Precigen Inc
2024/06/01	08 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/06/01	08 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/06/01	08 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/06/01	08 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/06/01	08 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PGEN	Precigen Inc
2024/05/29	05 : 48	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:PGEN	Precigen Inc
2024/05/29	05 : 44	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:PGEN	Precigen Inc
2024/05/24	06 : 00	PR Newswire (US)	Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting	NASDAQ:PGEN	Precigen Inc
2024/05/15	06 : 23	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PGEN	Precigen Inc
2024/05/15	06 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PGEN	Precigen Inc
2024/05/15	05 : 05	PR Newswire (US)	Precigen Reports First Quarter 2024 Financial Results and Business Updates	NASDAQ:PGEN	Precigen Inc
2024/05/09	05 : 05	PR Newswire (US)	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting	NASDAQ:PGEN	Precigen Inc